| 1 |
Development of novel AAV-based **** gene therapy for hearing loss |
| Gene & Nucleic acids |
Genetic hearing loss, Age-related hearing loss, Noise-induced hearing loss |
**** |
Hit |
Yonsei University |
RS-2026-25502919 |
|
| 2 |
Development of a Sarcopenia Therapeutic Based on New-Modality Protein Degradation Technology |
| TPD |
Sarcopenia |
**** (Master regulator of myogenic differentiation, chromatin-binding transcription regulator) |
Hit |
Mitos Therapeutic Inc. |
RS-2026-25502426 |
|
| 3 |
Hit optimization and lead generation activating NMJ for the treatment of Sarcopenia |
| Small molecules |
Sarcopenia |
****receptor |
Hit |
AVENTI Inc. |
RS-2025-02213042 |
|
| 4 |
Discovery of hit/lead compounds for sepsis treatment targeting ASM pathogenesis via immune and intestinal barrier permeability mechanisms |
| Small molecules |
Sepsis |
ASM |
Hit |
K-MEDI hub |
RS-2025-02213034 |
|
| 5 |
Hit optimization and lead generation activating PROKR1 to prevent and treat sarcopenia |
| Small molecules |
Sarcopenia |
PROKR1 agonist |
Hit |
Seoul National University |
RS-2024-00336938 |
|
| 6 |
Development of PROTAC-based **** degrader for promoting cartilage regeneration in osteoarthritis |
| TPD |
Osteoarhtritis |
Tankyrase |
Hit |
Seoul National University |
RS-2023-00217266 |
|
| 7 |
Identification a lead small-molecule drug to treat osteoarthritis through a cartilage regeneration mechanism |
| Small molecules |
Osteoarthritis |
OSCAR |
Hit |
KaiPharm Co., Ltd. |
RS-2022-00167006 |
|
| 8 |
Exercise-induced myokine CLCF1, a novel potential treatment for sarcopenia |
| rProtein |
Sarcopenia |
CLCF1 |
Hit |
Korea Research Institute of Bioscience and Biotechnology |
HN22C0330 |
|
| 9 |
Bone-delivered therapeutic antibody for osteoporosis based on clinically verified, innovative mode of action |
| Antibody |
Osteoporosis |
Cathepsin K |
Hit |
Ewha Women's University |
HN21C0317 |
|
| 10 |
Development of lead compound for treatment of hearing loss caused by cisplatin |
| Small molecules |
Hearing loss |
DRAK1, ADCK4, CDC42BPA |
Hit |
Kyungpook National University |
HN21C0107 |
|
| 11 |
Development of T cell-recruiting bispecific antibodies targeting blood antigen-specific B cells for ABO-incompatible solid organ transplantation |
| Antibody |
Organ Failure (incompatible blood type) |
ABO BCR, CD3 |
Hit |
Korea Advanced Institute of Science and Technology |
HN21C1024 |
|
| 12 |
Development of peptide T against sarcopenia in a form of muscle-specific delivered fusion peptides |
| rProtein |
Sarcopenia |
TLQP21 |
Hit |
Asan Medical Center |
HN21C0976 |
|
| 13 |
Identification of HDAC6 Inhibitor Lead Compounds for the Development of Renal Fibrosis Therapy |
| Small molecules |
Renal fibrosis |
HDAC6 |
Lead |
Sookmyung Women's University |
RS-2026-25502920 |
|
| 14 |
Cdo-Targeted Small Molecule Lead Compound Identification for Duchenne Muscular Dystrophy (DMD) Therapy |
| Small molecules |
DMD |
CDO |
Lead |
AniMusCure Inc |
RS-2025-25451838 |
|
| 15 |
Development of the First-in-class Drug for Sarcopenia |
| Small molecules |
Sarcopenia |
mTORC2 |
Lead |
Aliad Biopharma Inc. |
RS-2025-02223270 |
|
| 16 |
Study on the Discovery of Lead Compounds for Lesch-Nyhan Syndrome Treatment Using Cell-Derived Vesicles Carrying HPRT1 mRNA and Proteins |
| Other-Bio. |
Lesch-Nyhan syndrome |
HPRT1 |
Lead |
MDimune Inc. |
RS-2024-00337778 |
|
| 17 |
Development of BKCa Channel Agonism Based New Drug Lead Compounds for Overactive Bladder Symptom |
| Small molecules |
Bladder disease |
BKCa |
Lead |
GIST |
RS-2023-00258812 |
|
| 18 |
Lead discovery and development of production process for
sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism |
| rProtein |
Sarcopenia |
NOTCH1 |
Lead |
NUON Bio |
RS-2022-00165803 |
|
| 19 |
Development of multi-functioning lead compounds for lymphedema |
| Small molecules |
Lymphedema |
Nrf2 |
Lead |
RAPPELER |
HN22C0095 |
|
| 20 |
A Study on the lead optimization for the development of new antibody drugs for androgenic alopecia and alopecia areata |
| Antibody |
Hair Loss |
CXCL12 |
Lead |
Epibiotech |
HN22C0027 |
|
| 21 |
Research on lead optimization of miRNA-based therapeutics for treatment of sarcopenia |
| Gene & Nucleic acids |
Sarcopenia |
Atrogin-1 |
Lead |
Aventi Inc. |
HN21C0500 |
|
| 22 |
Development of KV7.4 specific activator for the treatment of genetic hearing loss(DFNA2) |
| Small molecules |
Genetic Hearing Loss |
KV7.4 |
Lead |
Yonsei University |
HN21C0163 |
|
| 23 |
AAV gene therapy for Pendrin mutation-associated sensorineural hearing loss |
| rProtein |
DFNB4/PDS |
SLC26A4 |
Candidate |
ICM Co., Ltd. |
RS-2026-25503251 |
|
| 24 |
NUAK1-Targeting Candidate Generation through Optimization and Preclinical Advancement |
| Small molecules |
CKD |
NUAK1 |
Candidate |
Genome & Company |
RS-2025-25453255 |
|
| 25 |
Lead optimization for sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism |
| rProtein |
Sarcopenia |
NOTCH1 |
Candidate |
NB Science Co., Ltd. |
RS-2025-25453248 |
|
| 26 |
Development of a Kv7.4 selective activator for the treatment of sensorineural hearing loss (noise-induced, ototoxic, and hereditary) |
| Small molecules |
Sensorineural hearing loss (noise-induced, ototoxic, and hereditary) |
Kv7.4 |
Candidate |
iN Therapeutics |
RS-2024-00349857 |
|
| 27 |
Mitochondrial transplantation as a novel treatment for sensorineural hearing loss |
| Other-Bio. |
Hearing loss |
Sensorineural hearing loss (with mitochondrial defects) |
Candidate |
Paean Biotechnology Inc. |
RS-2023-00283926 |
|
| 28 |
Candidate optimization of ARBM-101 as an innovative Wilson's disease drug |
| rProtein |
Wilson disease |
Cu2+ |
Candidate |
ARBORMED |
RS-2023-00218925 |
|
| 29 |
Development of a Tie2-activating antibody for treating acute kidney injury (AKI) |
| Antibody |
Acute Kidney Injury |
Tie2 |
Candidate |
MabTics Co., Ltd. |
RS-2023-00217918 |
|
| 30 |
Development of a highly stable and safe macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others-Synth. |
MRI contrast agent |
Gd-ligand |
Candidate |
PharmGen Science, Inc. |
HN22C0196 |
|